Name, scope, and testing boundary
Narcolepsy-related genetic testing is a collective term for assays that analyze inherited markers associated with susceptibility to narcolepsy and use the findings as supporting clinical information or for research stratification. The most common current clinical offering is human leukocyte antigen HLA-DQB1*06:02 typing. Some combined assays also report HLA alleles such as DRB1 or DQA1, while research panels may include immune-regulatory loci or polygenic risk information. These tests measure inherited background; they do not measure a sleep state, the severity of daytime sleepiness, abnormal rapid eye movement sleep, or cerebrospinal-fluid hypocretin concentration.
“Related gene” does not mean that there is a single “narcolepsy gene” capable of determining disease on its own. HLA-DQB1*06:02 is a common allele rather than a rare disease-causing mutation. It has a strong association with narcolepsy type 1, yet it is also present in many people who never develop narcolepsy. Its association with narcolepsy type 2 is weaker, and some people with an established diagnosis do not carry the allele. A positive result therefore cannot establish the diagnosis, and a negative result cannot universally exclude it. Genetic testing does not replace a sleep-specialist history, properly conducted sleep testing, or cerebrospinal-fluid hypocretin testing when the latter is clinically indicated.
Disease biology and genetic association
Narcolepsy is a central disorder of hypersomnolence. Type 1 is generally associated with loss of hypocretin-producing neurons and hypocretin deficiency, with typical cataplexy serving as an important clinical clue. Type 2 is not defined by cataplexy or demonstrated hypocretin deficiency and is more heterogeneous in both case composition and biology. HLA molecules participate in antigen presentation and immune recognition. The strong DQB1*06:02 association with type 1 supports an immune-susceptibility background, but possession of the allele is not sufficient to cause neuronal loss and cannot predict when symptoms will appear.
Most cases are sporadic. Familial clustering accounts for only a minority and does not follow a simple autosomal-dominant, autosomal-recessive, or sex-linked pattern. Other HLA combinations, T-cell-receptor loci, and immune-related variants can modify population risk, but the effect of a single locus is usually limited; environmental exposures and factors not yet identified also contribute. Association strength changes with phenotype, ancestry composition, control selection, and diagnostic criteria. An odds ratio from a research cohort must not be converted directly into one individual’s lifetime probability of disease.
Specimens, typing methods, and analytical quality
Clinical HLA typing commonly uses DNA extracted from anticoagulated whole blood. A laboratory may also validate buccal-swab or saliva specimens. Methods include sequence-specific primer or probe amplification and sequencing-based typing, whereas consumer genotyping arrays often infer an HLA allele from a small set of marker variants. Direct typing, a tag single-nucleotide variant, and statistical imputation are not equivalent evidence. Strong linkage in one dataset does not ensure that a proxy identifies the target allele accurately in every ancestry group or every individual.
Patient and barcode identity, collection container, transport time and temperature, DNA quantity and purity, contamination control, positive and negative controls, repeatability, and allele-calling software can all affect the result. The HLA region is exceptionally polymorphic. A report should state the locus examined, typing resolution, versioned nomenclature, and method limitations. It should also make clear whether “not detected” means that DQB1*06:02 was directly absent, that some alleles were outside assay coverage, or that sample quality was inadequate. A third-party interpretation of consumer raw data should be confirmed by a suitably qualified laboratory using a clinically validated method before it enters medical decision-making.
Positive, negative, and indeterminate findings
A positive result generally means that one or two DQB1*06:02 alleles were detected and indicates a susceptibility background associated with some narcolepsy phenotypes. It does not show that hypocretin neurons have already been lost and cannot distinguish present disease, future disease, or lifelong non-disease. Because the allele is not rare among unaffected people, positive predictive value is particularly limited in an asymptomatic person or another population with a low pretest probability. The result must not be used to label a child, relative, or member of the general population as having narcolepsy.
A negative result may reduce the likelihood of typical narcolepsy type 1 in a particular clinical setting, but it does not close the diagnostic pathway. Genuine HLA-negative type 1 cases, although uncommon, exist; negative results are more frequent in type 2, and the result does not adjudicate secondary hypersomnolence or other central disorders of hypersomnolence. An “indeterminate,” low-resolution, or proxy-marker result must be interpreted through the actual method and coverage rather than collapsed into “negative.” Any probability statement should incorporate the assay’s population performance, the person’s phenotype, and the complete investigation, without misreporting relative risk as absolute risk.
Place in the narcolepsy diagnostic pathway
The central complaint requiring assessment is persistent, difficult-to-resist daytime sleepiness. Cataplexy, sleep paralysis, hallucinations at sleep onset or awakening, fragmented night-time sleep, and automatic behavior provide additional information. The latter features are not unique to narcolepsy. Insufficient sleep, circadian misalignment, obstructive sleep apnea, medication or substance effects, depression, and other neurological conditions can produce similar complaints. Safety assessment must also address irresistible sleep while driving, operating equipment, or working at height.
A standard diagnostic pathway usually combines a detailed history, documentation of sufficient sleep and a stable schedule, exclusion or effective management of other causes, and—under suitable conditions—attended overnight polysomnography followed by a multiple sleep latency test. Insufficient sleep, shift work, delayed sleep phase, uncontrolled sleep-disordered breathing, and sedating, alerting, or REM-modulating medicines, including withdrawal rebound, can distort the findings. Selected suspected type 1 cases may undergo cerebrospinal-fluid hypocretin measurement for a specialist indication. A genetic result is, at most, supporting context; it cannot bypass these conditions or allow a consumer report to substitute for a sleep-specialist diagnosis.
Appropriate uses, non-uses, and ethics
HLA typing may sometimes contribute supporting information when the phenotype is atypical, other findings conflict, or a specialist team is considering whether a more invasive investigation would be informative. It can also support ethically approved case stratification, epidemiology, and mechanistic research. Testing should be ordered because the result can answer a defined question, not merely because blood collection is easy or the test name sounds conclusive. Population screening of asymptomatic people, prediction of age at onset from a positive allele, and dismissal of strong clinical evidence after a negative result are not supported uses.
The result should not be used to start or stop wake-promoting, anticataplectic, or other treatment without clinical evaluation. On its own it cannot determine fitness to drive, learn, or work; insurance risk; reproductive choices; or whether a relative is affected. Before testing, the person should understand possible findings, limited clinical utility, information shared with relatives, incidental findings, specimen retention, and secondary data use. Afterward, there should be access to questions for sleep medicine, medical genetics, or genetic-counseling professionals. For children and people unable to provide independent consent, the immediate medical benefit must also be weighed against future autonomy.
Selecting a service, reading a report, and follow-up
Before choosing a service, confirm whether the exact assay directly covers HLA-DQB1*06:02, the accepted specimen and method, typing resolution, failure and repeat rules, laboratory qualification, intended population, reporting time, and policies for data retention and deletion. An interpretable report should identify the person and specimen, method and coverage, detected or undetected alleles, limitations, authorizing professional, and issue date. A statement such as “high risk of narcolepsy” without the target allele and interpretive basis is insufficient for clinical use.
Someone with uncontrollable daytime sleep episodes, possible emotion-triggered loss of muscle tone, or sleepiness that already compromises road or occupational safety needs timely sleep-specialist assessment rather than a wait for a mail-order genetic test. A person who receives a positive result need not panic or restrict ordinary life on that basis; the original report should be reviewed with the phenotype by a qualified professional. Typical symptoms still warrant evaluation after a negative result. Repeat testing, broader typing, or family testing is meaningful only when it can change the differential diagnosis, counseling, or a defined research plan.